Clinical Trials – Protocol Status

CECOG performs high-quality clinical trials in Oncology.
For criteria for qualification of centers including requirements defined by Good Clinical Practice,
please send an e-mail to cecog@cecog.at


Colorectal Cancer

  • CECOG/DREAM (MO18420)

    Phase III study of an optimized chomotherapy + Avastin ® Strategy + Tarceva ® in metastatic colorectal cancer. Optimox 3-Tarceva ® Study. C04-2.

    Status: successfully closed after recruitment

  • CECOG/CORE.1.2.001

    A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX 6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer.

    Status: successfully closed after recruitment

  • CECOG/CORE.1.2.002

    A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + weekly Cetuximab versus FOLFOX4 + bi-weekly Cetuximab as first-line therapy in patients with metastatic colorectal cancer.

    Status: successfully closed after recruitment

Pancreatic Cancer

  • CECOG/PAN 1.3.001, SAKK 44/00

    Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer.
    A randomized phase III trial. SAKK 44/00

    Status: successfully closed after recruitment

Breast Cancer

  • CECOG/BC1.2.001

    A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combination with lapatinib for metastatic disease.

    Status: recruiting

  • CECOG/BC.1.3.005

    A randomized phase III trial of Paclitaxel plus Bevacizumab versus Capecitabine plus Bevacizumab for the first line treatment of HER2-negative locally recurrent or metastatic breast cancer.

    Status: successfully closed after recruitment

  • CECOG/BREAST.2.2.005

    A Randomized Phase II Study of Dose-Dense Fluorouracil plus Epirubicin75 plus Cyclophosphamide (FEC75) and Fluorouracil plus Epirubicin90 plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer

    Status: successfully closed after recruitment

  • CECOG/BC.1.3.002

    A Randomized Phase III Study Comparing Concomitant Docetaxel plus Gemcitabine to Sequential Therapy of Docetaxel followed by Gemcitabine in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients.

    Status: successfully closed after recruitment

  • CECOG/GBG

    Eine multizentrische Studie der Phase III zum Vergleich von Capecitabin alleine oder in Kombination mit Trastuzumab bei Patientinnen mit HER2 positiver metastasierter Brustkrebserkrankung und Progression nach vorheriger Behandlung mit Trastuzumab (Behandlung nach Progression).

    A multicenter randomized phase III study to compare capecitabine alone versus capecitabine with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with taxanes and trastuzumab (Treatment Beyond Progression, TBP).

    Status: successfully closed after recruitment

  • Phase III Study of Gemcitabine/Epirubicin/Paclitaxel Combination versus Standard 5-Fluorouracil/Epirubicin/Cyclophosphamide Combination as First Line Chemotherapy in Metastatic Breast Cancer: GET versus FEC
    (CECOG-BM1)

    Status: successfully closed after recruitment

    Published in: Proc. Am. Soc. Clin. Oncol. 25:26, 2003 and J. Clin. Oncol. 2005 Mar 1; 23(7):1401-8

Esophago-Gastric Cancer

  • CECOG/ESGAS 1.2.001

    Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally recurrent esophagogastric cancer previously untreated with chemotherapy for advanced disease

    Status: successfully closed after recruitment

  • CECOG/ESGAS 1.2.002

    A Phase II Study of Irinotecan, mitomycin C and capecitabine as second line chemotherapy for patients with metastatic or locally recurrent esophago-gastric cancer previously treated with chemotherapy for advanced disease.

    Status: successfully closed after recruitment

Non Small Cell Lung Cancer

  • CECOG participated in the ALIMTA – H3E-MC-JMEN Trial

    A phase III, double-blinded, placebo-controlled study of Pemetrexed plus best supportive care vs. best supportive care as maintenance therapy immediately following induction treatment for advanced Non-Small Cell Lung Cancer.

    Status: successfully closed after recruitment

  • CECOG/NSCLC.3.2.002

    A Phase II Trial of Dose-Dense Paclitaxel and Cisplatin as Neo- Adjuvant Chemotherapy for Operable Stage II and IIIA Non-Small Cell Lung Cancer

    Status: successfully closed after recruitment

  • Gemtax III

    Phase III comparing first line combination therapy versus sequential chemotherapy with Docetaxel and Gemcitabine in advanced Non Small Cell Lung Cancer (NSCLC)
    A cooperation with the Thoraxklinik Heidelberg, Germany.

    Status: successfully closed after recruitment

  • CECOG/NSCLC.2.2.001

    An open, randomized, multicentre, Phase II Pilot Study of Docetaxel and Cisplatin in the adjuvant treatment of Non-Small Cell Lung Cancer (NSCLC)
    Stage I-II

    Status: successfully closed after recruitment

  • Gemcitabine and Cisplatin With and Without Subsequent Maintenance Therapy with Single Agent Gemcitabine in Stage IV Non-small Cell Lung Cancer. A Randomized, Multicentric Study
    (CECOG-NSCLC1)

    Status: successfully closed after recruitment

    Published in : Lung Cancer 41, Suppl. 2:O-88, 203 and Lung Cancer 2006 May; 52(2):155-63

Gastrointestinal Stromal Tumours

  • CECOG/GIST 1.2.001

    Open-label Trial of Glivec in Patients with Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing c-kit

    Status: successfully closed after recruitment

  • GIST 1.2.002 Molecular Substudy

    Molecular mechanisms associated with response/resistance to Glivec in patients with unresectable or metastatic malignant gastrointestinal stromal tumur expressing c-kit.

    Status: successfully closed after recruitment

Prostate Cancer

  • CECOG/PROSTATE 1.2.001

    A randomised open-label (ZOMETA® + hormonal ablation vs. hormonal ablation alone) multicenter prospective clinical study to show the efficacy of intravenous ZOMETA® (zoledronic acid) 4 mg for prevention of bone metastases in hormone-naïve high risk patients with locally advanced prostate cancer.

    Status: successfully closed after recruitment

For further information on inclusion and exclusion criteria, dosages and schedules as well as other necessary information,
please send an e-mail to cecog@cecog.at